CN112203660B - 用于治疗银屑病关节炎的方法 - Google Patents

用于治疗银屑病关节炎的方法 Download PDF

Info

Publication number
CN112203660B
CN112203660B CN201980034599.1A CN201980034599A CN112203660B CN 112203660 B CN112203660 B CN 112203660B CN 201980034599 A CN201980034599 A CN 201980034599A CN 112203660 B CN112203660 B CN 112203660B
Authority
CN
China
Prior art keywords
treatment
patient
use according
psoriatic arthritis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980034599.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112203660A (zh
Inventor
P·哈里森
L·梅勒内尔斯
C·T·塔塞斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Galapagos NV
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV, Alfasigma SpA filed Critical Galapagos NV
Publication of CN112203660A publication Critical patent/CN112203660A/zh
Application granted granted Critical
Publication of CN112203660B publication Critical patent/CN112203660B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980034599.1A 2018-05-24 2019-05-23 用于治疗银屑病关节炎的方法 Active CN112203660B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits
GB1808575.3 2018-05-24
PCT/EP2019/063283 WO2019224283A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis

Publications (2)

Publication Number Publication Date
CN112203660A CN112203660A (zh) 2021-01-08
CN112203660B true CN112203660B (zh) 2024-12-31

Family

ID=62812304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034599.1A Active CN112203660B (zh) 2018-05-24 2019-05-23 用于治疗银屑病关节炎的方法

Country Status (10)

Country Link
US (2) US12329758B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801548A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021524472A (cg-RX-API-DMAC7.html)
KR (1) KR102955500B1 (cg-RX-API-DMAC7.html)
CN (1) CN112203660B (cg-RX-API-DMAC7.html)
AU (2) AU2019273664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101386A1 (cg-RX-API-DMAC7.html)
GB (1) GB201808575D0 (cg-RX-API-DMAC7.html)
MA (1) MA52738A (cg-RX-API-DMAC7.html)
WO (1) WO2019224283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2021308574A1 (en) * 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
EP4287299A4 (en) 2021-01-29 2025-01-01 LG Chem, Ltd. ELECTRODE
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482273A (zh) * 2009-06-26 2012-05-30 加拉帕戈斯股份有限公司 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
CN104379173A (zh) * 2012-06-22 2015-02-25 加拉帕戈斯股份有限公司 用于治疗炎症的氨基三唑并吡啶及其药物组合物
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN107531694A (zh) * 2015-04-13 2018-01-02 加拉帕戈斯股份有限公司 用于治疗炎性疾病的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2004039816A1 (ja) 2002-10-29 2004-05-13 Shionogi & Co., Ltd. セフェム化合物の無機酸塩の結晶
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び/又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
FI3595667T3 (fi) * 2017-03-14 2024-01-12 Galapagos Nv Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482273A (zh) * 2009-06-26 2012-05-30 加拉帕戈斯股份有限公司 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
CN104379173A (zh) * 2012-06-22 2015-02-25 加拉帕戈斯股份有限公司 用于治疗炎症的氨基三唑并吡啶及其药物组合物
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN107531694A (zh) * 2015-04-13 2018-01-02 加拉帕戈斯股份有限公司 用于治疗炎性疾病的方法

Also Published As

Publication number Publication date
WO2019224283A1 (en) 2019-11-28
US20260108530A1 (en) 2026-04-23
JP7751362B2 (ja) 2025-10-08
CA3101386A1 (en) 2019-11-28
AU2025202777A1 (en) 2025-05-08
EP3801548A1 (en) 2021-04-14
JP2021524472A (ja) 2021-09-13
JP2024069223A (ja) 2024-05-21
MA52738A (fr) 2021-04-14
AU2019273664A1 (en) 2021-01-21
JP2025183397A (ja) 2025-12-16
US12329758B2 (en) 2025-06-17
US20210299135A1 (en) 2021-09-30
KR102955500B1 (ko) 2026-04-21
KR20210013168A (ko) 2021-02-03
AU2019273664B2 (en) 2025-01-23
GB201808575D0 (en) 2018-07-11
CN112203660A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
JP7751362B2 (ja) 乾癬性関節炎の治療方法
US11524964B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220267342A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
JP2018537418A (ja) インターロイキン17(il−17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
US11773106B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP2022105160A (ja) 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和gm-csf
JP2019534304A (ja) 炎症性疾患の治療のための化合物及びその医薬組成物
CN121969374A (zh) 使用ly3871801治疗自身免疫性和炎症性疾病的剂量方案
TW202126329A (zh) 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
EP4356963A2 (en) Treating spondyloarthritic and psoriatic conditions with upadacitinib
Chaplin Janus kinase inhibitors for autoimmune disorders
Sadeq et al. Randomized clinical trials on the efficacy and safety of tocilizumab in subjects with Rheumatoid arthritis: a systematic review
Zhang et al. Preclinical characterization of the selective Jak1 inhibitor Lw402 for treatment of rheumatoid arthritis
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20240398790A1 (en) Treating spondyloarthritic conditions with upadacitinib
Juganaru et al. Therapeutic options in refractory anti-MDA5+ dermatomyositis triggered by SARS-CoV-2 infection
Humby et al. O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Hawkins 54 Rheumatoid Arthritis and Osteoarthritis
CN120957720A (zh) 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用
Martín-Varillas et al. AB1017 WHAT IS THE CURRENT SITUATION OF THE PAEDIATRIC RHEUMATOLOGY TRANSITION CARE UNITS?
TW202511290A (zh) 一種重組抗IL-23p19抗體治療中重度銀屑病的方法
Dragoi et al. OP0173 inspiratory muscle training as a method for improving aerobic capacity and pulmonary function in patients with ankylosing spondylitis: a randomized controlled study
Moltό et al. THU0357 No specific impact of concomitant fibromyalgia on the anti tnf treatment effect in axial spondyloarthritis patients without radiographic structural damage or objective signs of inflammation
Mohammed Anti-CD-20 Therapy in Refractory Adult Still’s Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240403

Address after: Bologna, Italy

Applicant after: ALFASIGMA S.P.A.

Country or region after: Italy

Address before: Mechelen

Applicant before: GALAPAGOS N.V.

Country or region before: Belgium

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant